Printer Friendly

CRYOMEDICAL SCIENCES ADDS ROBERT SCHOELLHORN, FORMER CEO AND CHAIRMAN OF ABBOTT LABORATORIES, TO BOARD OF DIRECTORS

CRYOMEDICAL SCIENCES ADDS ROBERT SCHOELLHORN, FORMER CEO AND CHAIRMAN
 OF ABBOTT LABORATORIES, TO BOARD OF DIRECTORS
 ROCKVILLE, Md., Sept. 24 /PRNewswire/ -- Cryomedical Sciences, Inc. (NASDAQ: CMSI), today announced that Robert A. Schoellhorn, former president, CEO and chairman of Abbott Laboratories, has joined its board of directors, bringing its membership to five.
 Schoellhorn joined Abbott as executive vice president of its hospital group in 1973. He was elected president in 1976, chief executive officer in 1979 and chairman in 1981. At the time he joined Abbott, the company had annual sales of approximately $600 million and when he retired in September 1990, annual sales had grown to more than $6 billion worldwide.
 According to J.J. Finkelstein, the president and CEO of Cryomedical Sciences: "We are extremely pleased to be able to attract someone with the vast experience and accomplishments of a Bob Schoellhorn to serve on our board of directors. Not only does this speak highly of Cryomedical Sciences but, more importantly, we will now have one of the leaders in our industry helping guide us as we seek to become a major company in the health care field."
 Schoellhorn has served on a number of boards inside and outside the pharmaceutical industry including, SCM Corp., Pillsbury, ITT and Shell Oil. In addition he is past chairman of the Pharmaceutical Manufacturers Association, the Health Industry Manufacturers Association, and the Food and Drug Law Institute, among others.
 Cryomedical Sciences, Inc., is a biomedical company engaged in the research, development, manufacture and marketing of products for use in low temperature medicine. In June 1992, Cryomedical introduced the CMS AccuProbe system, a cryosurgical instrument used to treat inoperable cancers and cancerous conditions where traditional surgery or radiotherapy offers unacceptable side effects. These include minimally invasive procedures in many cases, resulting in reduced blood loss and trauma to the patient, faster recovery and substantially lower health care costs.
 -0- 9/24/92
 /NOTE: CMS AccuProbe is a trademark./
 /CONTACT: Edward Segal, STG Marketing Communications, 202-333-7966, for Cryomedical Sciences, or J.J. Finkelstein of Cryomedical Sciences, 301-417-7070/
 (CMSI) CO: Cryomedical Sciences, Inc. ST: Maryland IN: MTC SU: PER


DC -- DC005 -- 2994 09/24/92 10:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 24, 1992
Words:362
Previous Article:FLEET BANK LOWERS CREDIT CARD INTEREST RATE; PROMOTIONAL CAMPAIGN FEATURES 11.9 PERCENT FOR ALL CONSUMERS
Next Article:AMSCO INTERNATIONAL, INC. FILES TO REGISTER WITH SEC OFFERING OF $100 MILLION OF STEP-UP CONVERTIBLE SUBORDINATED DEBENTURES DUE 2002
Topics:


Related Articles
CRYOMEDICAL SCIENCES ANNOUNCES SHIPMENT OF CMS ACCUPROBE SYSTEMS
CRYOMEDICAL SCIENCES' ACCUPROBE IS USED SUCCESSFULLY IN PROSTATE SURGERY AT UNIVERSITY OF TEXAS CANCER CENTER
CRYOMEDICAL SCIENCES ANNOUNCES FISCAL YEAR 1993 BUSINESS AND FINANCIAL RESULTS; 35 CMS ACCUPROBE SYSTEMS SOLD; ORDER BACKLOG TOPS $10 MILLION
CRYOMEDICAL SCIENCES, INC. ANNOUNCES EUROPEAN DISTRIBUTION AGREEMENT WITH B&K MEDICAL A/S
SOMANETICS APPOINTS FORMER ABBOTT LAB EXECUTIVE, H. RAYMOND WALLACE AS CHAIRMAN OF THE BOARD
CRYOMEDICAL SCIENCES ADDS HENRY PIETRASZEK TO BOARD OF DIRECTORS
BIOSOURCE INTERNATIONAL NAMES NEW BOARD MEMBER
Court Finds No Trade Secrets Imparted in CMSI vs. ENDOcare
Abbott Announces New Top Management Team

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters